{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Abel B"],"funding":["Intramural NIH HHS"],"pagination":["180-192"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6608608"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["96(2)"],"pubmed_abstract":["P-glycoprotein (P-gp) is a multidrug transporter that is expressed on the luminal surface of epithelial cells in the kidney, intestine, bile-canalicular membrane in the liver, blood-brain barrier, and adrenal gland. This transporter uses energy of ATP hydrolysis to efflux from cells a variety of structurally dissimilar hydrophobic and amphipathic compounds, including anticancer drugs. In this regard, understanding the interaction with P-gp of drug entities in development is important and highly recommended in current US Food and Drug Administration guidelines. Here we tested the P-gp interaction of some A<sub>3</sub> adenosine receptor agonists that are being developed for the treatment of chronic diseases, including rheumatoid arthritis, psoriasis, chronic pain, and hepatocellular carcino"],"journal":["Molecular pharmacology"],"pubmed_title":["Evidence for the Interaction of A<sub>3</sub> Adenosine Receptor Agonists at the Drug-Binding Site(s) of Human P-glycoprotein (ABCB1)."],"pmcid":["PMC6608608"],"funding_grant_id":["ZIA BC010030","ZIA DK031117"],"pubmed_authors":["Durell SR","Jacobson KA","Abel B","Murakami M","Vahedi S","Tosh DK","Ambudkar SV"],"additional_accession":[]},"is_claimable":false,"name":"Evidence for the Interaction of A<sub>3</sub> Adenosine Receptor Agonists at the Drug-Binding Site(s) of Human P-glycoprotein (ABCB1).","description":"P-glycoprotein (P-gp) is a multidrug transporter that is expressed on the luminal surface of epithelial cells in the kidney, intestine, bile-canalicular membrane in the liver, blood-brain barrier, and adrenal gland. This transporter uses energy of ATP hydrolysis to efflux from cells a variety of structurally dissimilar hydrophobic and amphipathic compounds, including anticancer drugs. In this regard, understanding the interaction with P-gp of drug entities in development is important and highly recommended in current US Food and Drug Administration guidelines. Here we tested the P-gp interaction of some A<sub>3</sub> adenosine receptor agonists that are being developed for the treatment of chronic diseases, including rheumatoid arthritis, psoriasis, chronic pain, and hepatocellular carcino","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Aug","modification":"2025-04-18T18:11:19.187Z","creation":"2021-02-20T04:55:43Z"},"accession":"S-EPMC6608608","cross_references":{"pubmed":["31127007"],"doi":["10.1124/mol.118.115295"]}}